×
About 2,033 results

ALLMedicine™ Hypogammaglobulinemia Center

Research & Reviews  662 results

Good Syndrome: Cytomegalovirus retinitis case challenge.
https://doi.org/10.1097/ICB.0000000000001316
Retinal Cases & Brief Reports; Baquero-Ospina P, Cantu-Rosales C et. al.

Feb 3rd, 2023 - To describe cytomegalovirus retinitis in a patient with Good syndrome (hypogammaglobulinemia and thymoma), ocular progression despite treatment, and fatal outcome. A 71-year-old woman with unilateral panuveitis of unknown cause and a history of th...

Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Period...
https://doi.org/10.1007/s10875-023-01441-7
Journal of Clinical Immunology; Li Y, Deng M et. al.

Feb 3rd, 2023 - Sideroblastic anemia, immunodeficiency, periodic fevers, and developmental delay (SIFD) is an autosomal recessive syndrome caused by biallelic loss-of-function variant of tRNA nucleotidyl transferase 1 (TRNT1). Efficacious methods to treat SIFD ar...

Mantle Cell Lymphoma
http://emedicine.medscape.com/article/203085-overview

Jan 31st, 2023 - Practice Essentials Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. MCL represents 2-10% of all non...

Mantle Cell Lymphoma
https://emedicine.medscape.com/article/203085-overview

Jan 31st, 2023 - Practice Essentials Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. MCL represents 2-10% of all non...

Mantle Cell Lymphoma
https://emedicine.medscape.com/article/203085-print

Jan 31st, 2023 - Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. MCL represents 2-10% of all non-Hodgkin lymphomas. ...

see more →

Drugs  11 results see all →

Clinicaltrials.gov  44 results

Genetic Studies of Chronic Active Epstein-Barr Disease
https://clinicaltrials.gov/ct2/show/NCT00032513

Jan 26th, 2023 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
https://clinicaltrials.gov/ct2/show/NCT02579967

Jan 26th, 2023 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
https://clinicaltrials.gov/ct2/show/NCT04339777

Jan 25th, 2023 - Background: With the availability of whole exome sequencing (WES) and whole genome sequencing (WGS) for patients with suspected inborn errors of immunity (IEI), the number of recognized IEI has increased in recent years to over 400 distinct immune...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

Jan 19th, 2023 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobuli...
https://clinicaltrials.gov/ct2/show/NCT05645107

Jan 18th, 2023 - The primary purpose of the study is to evaluate whether weekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in participants with hypo...

see more →

News  96 results

Treatments Branch Out in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/treatments-branch-out-in-newly-diagnosed-and-relapsed-refractory-multiple-myeloma

Nov 17th, 2022 - Therapeutic strategies such as defining the optimal timing of autologous stem cell transplant (ASCT), implementing CAR T-cell agents, and introducing BCMA-directed bispecific antibodies are building on current standards of care (SOCs) in multiple ...

Addressing Adverse Events With Bispecific Antibodies with Focus on CRS Management
https://www.onclive.com/view/addressing-adverse-events-with-bispecific-antibodies-with-focus-on-crs-management

Oct 11th, 2022 - Transcript: Ajai Chari, MD:But putting that aside, let’s talk a little bit about adverse effects, too. Does anybody want to start with the adverse effects of BCMA [B-cell maturation antigen] as a class? And also distinguishing if you think there ...

Bispecific Antibody ABBV-383 Looks to Fill Unmet Need in Heavily Pretreated Multiple Myeloma
https://www.onclive.com/view/bispecific-antibody-abbv-383-looks-to-fill-unmet-need-in-heavily-pretreated-multiple-myeloma

Aug 28th, 2022 - Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma, according to updated results from a phase 1 trial (NCT03933735) presented ...

Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL
https://www.onclive.com/view/individualized-care-drives-treatment-focus-in-aml-dlbcl-and-cll

Jul 11th, 2022 - Future advances in leukemia and lymphoma treatment will arise from careful consideration of current management strategies, explained Ehab Atallah, MD, who emphasized the importance of framing future directions around present unmet needs, such as r...

Liso-cel Approval Provides Earlier, Expanded Access to CAR T-cell Therapy in Second-line LBCL
https://www.onclive.com/view/liso-cel-approval-provides-earlier-expanded-access-to-car-t-cell-therapy-in-second-line-lbcl

Jun 29th, 2022 - Second-line lisocabtagene maraleucel (liso-cel; Breyanzi) provides an earlier CAR T-cell treatment option that improves survival outcomes and produces a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma (LBCL), i...

see more →